Endpoints News—OnKure Therapeutics has lined up $60 million in a new private funding round, adding to the CU Boulder spinout’s bank account as it works through a Phase II trial. The startup is attempting to create an inhibitor of histone deacetylases, or HDACs, which are DNA-manipulating enzymes that alter how genes get expressed.